Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | TET3 | O43151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.47 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.47 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.47 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.47 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 9/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12020396 | 1.00 | HDAC4 (0.47) | HDAC4TET3KMT2AFBXL19CXXC5 | |
| SCHEMBL349711 | 0.84 | TET3 (0.48) | HDAC4TET3KMT2AFBXL19CXXC5 | |
| SCHEMBL349710 | 0.84 | TET3 (0.48) | HDAC4TET3KMT2AFBXL19CXXC5 | |
| SCHEMBL14541574 | 0.84 | TET3 (0.48) | HDAC4TET3KMT2AFBXL19CXXC5 | |
| SCHEMBL12020374 | 0.83 | HDAC4 (0.50) | HDAC4HSD11B1MAOAMAOBKDM1A | |
| SCHEMBL1003298 | 0.83 | HDAC4 (0.50) | HDAC4HSD11B1MAOAMAOBKDM1A | |
| SCHEMBL25382284 | 0.82 | AKR1C1 (0.43) | HDAC4KMT2AMAOBAKR1C1ALDH1A1 | |
| SCHEMBL11481441 | 0.82 | CCR2 (0.51) | HDAC4TET3KMT2AFBXL19CXXC5 | |
| SCHEMBL25382548 | 0.81 | TET3 (0.43) | HDAC4TET3KMT2AFBXL19CXXC5 | |
| SCHEMBL14541572 | 0.81 | HDAC4 (0.47) | HDAC4HSD11B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388536-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4486444-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | F. Hoffmann-La Roche AG (CH) | 2025-01-08 | — | — | EP | disclosed |
| CN-118871422-A | 3-Alkynyl carboxamides as AEP modulators | 豪夫迈·罗氏有限公司 | 2024-10-29 | — | — | CN | disclosed |
| WO-2023165943-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-09-07 | — | — | WO | disclosed |
| EP-1532122-B1 | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK SHARP & DOHME (US) | 2011-12-14 | — | — | EP | disclosed |
| US-7875642-B2 | 3-[1-(4-Chlorophenyl)-trans-3-fluorocyclobutyl]-4,5-dicyclopropyl-r-4H-1,2,4-triazole anhydrate; Type 2 diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, and cognitive impairment | MERCK SHARP & DOHME CORP. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20090186928-A1 | Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1 | MERCK SHARP & DOHME LLC | 2009-07-23 | — | — | US | disclosed |
| US-7179802-B2 | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-20040106664-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK SHARP & DOHME LLC | 2004-06-03 | — | — | US | disclosed |
| US-6730690-B2 | DELAYING THE ONSET OR REDUCING THE RISK OF DEVELOPING ATHEROSCLEROSIS IN A HUMAN PATIENT COMPRISING ADMINISTERING TO SAID PATIENT AN EFFECTIVE AMOUNT OF A COMPOUND OF INVENTION AND AN HMG-COA REDUCTASE INHIBITOR | MERCK & CO., INC. | 2004-05-04 | — | — | US | disclosed |
| US-20040048912-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | MERCK SHARP & DOHME LLC | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048912-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | HSD11B1, HSD17B1, HSD11B2 | HDAC4 1252/4885TET3 4143/4885KMT2A 3350/4885 |
| US-20040106664-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | HSD11B1, HSD11B2, HSD17B1 | HDAC4 1567/4885TET3 4074/4885KMT2A 3572/4885 |
| US-20250388536-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | CNR2, CNR1, FAAH2 | HDAC4 1844/4885TET3 4255/4885KMT2A 1448/4885 |
| US-20090186928-A1 | Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1 | HSD11B1, HSD3B1, HSD11B2 | HDAC4 857/4885TET3 4063/4885KMT2A 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.